Anzeige
Meldung des Tages: Gold bei 5.250 USD – Dieser 37-Mio.-€-Goldentwickler sitzt auf einem möglichen $2-Milliarden-Projekt!!

Edgewise Therapeutics News

Aktie
WKN:  A2QRZ8 ISIN:  US28036F1057 US-Symbol:  EWTX Branche:  Biotechnologie Land:  USA
29,96 $
-0,99 $
-3,20%
26,021 € 20:59:58 Uhr
Depot/Watchlist
Marktkapitalisierung *
2,10 Mrd. €
Streubesitz
-
KGV
-15,36
Index-Zuordnung
-

Edgewise Therapeutics News

10.03.26 - PR Newswire
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up PR ...
04.03.26 - PR Newswire
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 PR Newswire
03.03.26 - PR Newswire
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference PR Newswire
02.03.26 - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
26.02.26 - PR Newswire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs PR Newswire
05.02.26 - PR Newswire
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 PR Newswire
02.02.26 - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
13.01.26 - PR Newswire
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 PR Newswire
06.01.26 - PR Newswire
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 PR Newswire
05.01.26 - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
24.12.25 - PR Newswire
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-​HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in ...
02.12.25 - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
20.11.25 - PR Newswire
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors PR Newswire
12.11.25 - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
10.11.25 - PR Newswire
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers PR Newswire
07.11.25 - PR Newswire
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Edgewise Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
06.11.25 - PR Newswire
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights PR Newswire
03.11.25 - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
02.10.25 - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
02.10.25 - PR Newswire
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society PR ...

Newssuche

Videos

newspaper
10.03.26 -6,06%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »